Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle and possibly beta-adrenergic stimulation.
## Primary Indications
* Treatment of peripheral vascular disease, such as intermittent claudication.
* Adjunctive treatment in cerebrovascular insufficiency.
* Treatment of Raynaud's disease and other vasospastic disorders.
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily.
* **Maximum:** Generally not to exceed 80 mg per day. Specific maximums may vary by indication and local protocol.
## Pediatric Dosing
* There is no established pediatric dosing for isoxsuprine hydrochloride. Use is generally not recommended in pediatric patients due to a lack of safety and efficacy data.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for hepatic or renal impairment, but caution is advised. Prescribers should consider reduced doses and increased monitoring in these populations.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Administering the drug intravenously (IV) is contraindicated.
* Use with extreme caution in patients with severe arteriosclerosis or heart disease.
## Adverse Effects
* **Common:** Nausea, vomiting, stomach upset, dizziness, weakness, flushing, rash, blurred vision.
* **Less Common:** Hypotension, tachycardia, chest pain, paradoxical bronchospasm (especially in asthmatic patients), drowsiness.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive medications, leading to additive hypotension.
* **Other Vasodilators:** Concomitant use with other vasodilators may increase the risk of hypotension.
## Monitoring
* Monitor blood pressure and heart rate.
* Assess for improvement in symptoms related to peripheral vascular disease.
* Observe for signs of adverse effects.
## Clinical Pearls
* Isoxsuprine is primarily administered orally. Intravenous administration is contraindicated.
* Its efficacy in improving overall circulatory function is debated, and clinical evidence for significant benefit is limited.
* Use is generally reserved for patients unresponsive to other treatments or when a vasodilator is deemed appropriate after careful risk-benefit assessment.
* Discontinue use if adverse effects occur or if symptoms do not improve.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current official prescribing information and relevant clinical guidelines for definitive guidance before prescribing or administering any medication.
